The Board of Directors serves as an advisory and oversight board to the American Physician Scientists Association and the Executive Council. The board is made of physician-scientist stakeholders and leaders and of former/current members of the APSA Executive Council. Together this group of individuals not only maintain and guide the long term vision of the organization but they also retain the institutional memory for the organization.
Moshe Levi, MD obtained his degrees in Chemical Engineeringfrom Northwestern University (BS) and Stanford University (MS) and his medical degree from Albert Einstein College of Medicine. He completed his internship and residency training in internal medicine at Cornell Medical College and his fellowship training at the University of Colorado. He was in the faculty in the University of Texas Southwestern Medical Center from 1984-2002 and since 2002 at the University of Colorado where he is currently Professor of Medicine & Physiology and Biophysics & Bioengineering. He is a practicing Nephrologist and he also leads an active research lab investigating 1) the regulation of renal and intestinal phosphate transport, 2) obesity, diabetes and aging related kidney disease, and 3) atherosclerosis and vascular calcification.
Mr. Alexander Adami is an MD-PhD student at the University of Connecticut. He received a BS in Information Technology and Web Science from Rensselaer Polytechnic Institute in 2010. His current research includes asthma and the dynamics of the host-microbiome relationship as well as a small clinical project concerning the immunology of sickle cell disease. Alex oversees all of APSA's initiatives and committees as President of the Association. He previously served on the Public Relations Committee as Vice-Chair (2012-2014), Technology Chair (2014-2015), President-Elect (2015-2016), and University of Connecticut Institutional Representative (2011-2016).
Mr. Daniel Dellostrittois a sixth year MD/PhD student at Northeast Ohio Medical University (NEOMED) in Ohio. He completed his undergraduate education at Kent State University (KSU) and in 2010, he graduated Summa Cum Laude with Honors in Integrated Life Sciences. His research at Northeast Ohio Medical University focuses on diabetic oxidative stress and its effects on microvascular function, focusing on its regulation by the TRPV1 (Transient Receptor Potential Vanilloid 1) ion channel. At NEOMED. For his work, Daniel was awarded a prestigious American Heart Association Predoctoral grant. Mr. DelloStritto contributed to the creation of the MD/PhD program and was the co-founder of the local chapter of APSA. Furthermore, he has been involved with the Annual Meeting Planning Committee (2011-2015) as a member in 2011-2012 and a vice-chair for the 2013 Annual meeting and was Co-Chair with Ms. Sherry Wen for the 2014 Annual Meeting. Furthermore, Daniel was elected by to the role of President-Elect for APSA for the 2014-2015 EC and has continued on as President this year. His hopes are to continue to bring APSA to the forefront of physician-science leaders by making sure APSA continues to advocate on behalf of trainees.
Jaimo Ahn, MD, PhD, FACS is an Assistant Professor of orthopaedic surgery and Co-director of orthopaedic trauma at the Perleman School of Medicine at the University of Pennsylvania. He completed a fellowship in Orthopaedic Traumatology at the Hospital for Special Surgery / Weill Cornell Medical College (2008-2009) and Inselspital / University of Bern Switzerland, an internship and residency in orthopaedic surgery at the University of Pennsylvania (2003-2008) where he also received his MD-PhD in Cell & Molecular Biology (1995-2003) after his undergraduate degree from Stanford University. In addition to studying the education and development of physician-scientists, he co-manages a laboratory with a focus on molecular modulation of bone formation and healing and a clinical research program with a focus on prospective evaluation of orthopaedic trauma outcomes and surgical decision making. He is active in medical education, serving as Director of the orthopaedic clerkship, Assistant Director of the orthopaedic residency program, Steering Committee member of the MSTP at Penn. He has been a member of the USMLE test material development committee, currently writes for the Orthopaedic Boards, and enjoys reviewing for journals as varied as JAMA, Science Translational Medicine and the Journal of Bone and Joint Surgery and funding bodies such as the NIH, Departments of Defense / Veterans Affairs and Arbeitsgemeinschaft für Osteosynthesefragen Foundation. Outside of academics, he especially enjoys food, wine, travel and exercise with his wife. Dr. Ahn became a member of the APSA Board of Directors in April of 2007 and served as Chair in 2011-2013.
Hans Arora, M.D. Ph.D. is urology resident physician at the Cleveland Clinic Foundation Glickman Urological and Kidney Institute. He is a graduate of the Medical Scientist Training Program (MSTP) at the Northwestern University Feinberg School of Medicine, graduating Magna Cum Laude. He received his B.S. with Honors in Chemical Engineering from Pennsylvania State University, and completed his Ph.D. in the laboratory of Dr. Gayle Woloschak in the Department of Radiation Oncology. His dissertation research involved the use of titanium dioxide nanoparticles to overcome cancer chemotherapy drug resistance in ovarian cancer, the number one cause of gynecologic cancer death in women. Specifically he studied the effects of titanium dioxide-doxorubicin nanoconjugates, and their effects on the uptake, localization, and cytotoxicity as compared to free doxorubicin in a drug-resistance ovarian carcinoma model. Interestingly, he found that both free nanoparticles and nanoconjugates increased the uptake of transferrin, a marker for clathrin-mediated endocytosis. His prior research experiences include internships at the National Institutes of Health, the Armed Forces Radiobiology Research Institute, and Pennsylvania State University. His research has been presented at numerous national and international conferences, including the American Society for Radiation Oncology, the American Association for Cancer Research, and the Gordon Conference on Radiation Oncology, and has been supported by national and local research grants from the American Medical Association Foundation, the National Institutes of Health Center for Cancer Nanotechnology Excellence, and the Northwestern University Clinical and Translational Sciences Institute (NUCATS).
Hans continues to be active in the medical community throughout his time as a medical students and resident physician at the national, state, and local levels. He has served as National Chair of the Medical Student Section of the American Medical Association; Physician Advisory Board member of Building a Healthier Chicago; as well as a Trustee of the Illinois State Medical Society, Chicago Medical Society, and the American Physician Scientists Association. For his academic and professional accomplishments, he has been awarded the American Medical Association Foundation Excellence in Leadership Award, the Chicago Medical Society’s inaugural Outstanding Student Award, the Heller Award for Excellence in Clinical Medicine, and was inducted into the Alpha Omega Alpha Honor Medical Society. His continuing research interests involve the molecular mechanisms of disease in urologic oncology.
Lawrence (Skip) Brass
Lawrence (Skip) Brass, MD PhD is a graduate of Harvard College and Case Western Reserve University, where he received his MD and a PhD in biochemistry. After residency training in internal medicine he became a fellow in Hematology-Oncology at the University of Pennsylvania where he served as Vice Chair for Research in the Department of Medicine from 2004 to 2007, and is currently Professor of Medicine and Pharmacology. Dr. Brass became Associate Dean for Combined Degree and Physician Scholars Programs and Director of Penn’s Medical Scientist Training Program in 1998. He has been active at the national level in the development of training programs for physician-scientists and has served as President of the National Association of MD-PhD Programs, Chair of the AAMC GREAT section on MD-PhD training, and was a member of the NIH Physician-Scientist Workforce advisory group in 2013-2014. He is also a practicing hematologist whose research interests are in the fields of hemostasis and vascular biology. He has been continuously funded by the NIH HLBI since the mid-1980’s, has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, was an Established Investigator of the American Heart Association and is a recipient of the Distinguished Career Award from the International Society of Hemostasis and Thrombosis, the Christian R. and Mary F. Lindback Award for Distinguished Teaching from the University of Pennsylvania, and numerous teaching awards from students at the University of Pennsylvania Perelman School of Medicine.
Dania Daye, MD, PhD is currently a resident in diagnostic and interventional radiology at Massachusetts General Hospital and a clinical fellow in medicine at Harvard Medical School. She completed an internship year in internal medicine at Brigham and Women's Hospital. Dr. Daye graduated from the University of Pennsylvania MD-PhD program, with election to Alpha Omega Alpha. She completed her PhD in Bioengineering as an HHMI-NIBIB Interfaces scholar in imaging sciences. The focus of her PhD was on understanding the metabolo-genetic regulation of breast cancer recurrence using multi-nuclear magnetic resonance spectroscopy. As a medical student, Dr. Daye was selected as a Howard Hughes Medical Institute Gilliam fellow and a Paul and Daisy Soros fellow. To date, her research has resulted in a number of patents, peer-reviewed publications and multiple presentations and invited talks at both national and international meetings. For her research, Dr. Daye is the recipient of many awards that include the Association of American Physicians Stanley J. Korsmeyer Young Investigator Award, the Association of University Radiologists (AUR) Memorial Award and the J. George Teplick Memorial Award. In 2014, she was elected as a junior fellow of the International Society of Magnetic Resonance in Medicine (ISMRM). Ms. Daye served as the 2012-2013 President of the American Physician Scientists Association. During her tenure, she led recruitment efforts that resulted in a 30% increase in membership and in continued APSA representation in 94 U.S. medical schools. Ms. Daye also oversaw the launch of a new APSA website offering improved career development resources for physician-scientist trainees; and fostered a number of new partnerships between APSA and professional societies that included a new partnership with the Radiological Society of North America (RSNA). Ms. Daye previously served as chair and vice-chair of the APSA policy committee and remains involved in APSA’s various policy and data collection initiatives. For her local and national leadership roles, Ms. Daye was the recipient of the AMA Foundation Leadership Award.
Shwayta Kukreti, MD, PhD is resident who will be training in Radiology at UCLA. Currently she is pursuing her preliminary medicine year at the University of Illinois at Urbana-Champaign. In 2011 she completed the Medical Scholars MD/PhD Program at the University of Illinois-Urbana, Champaign. She received her PhD in Biophysics and Computational Biology in 2007 working at the Laboratory for Fluorescence Dynamics in collaboration with the Beckman Laser Institute and Medical Clinic at the University of California-Irvine. Dr. Kukreti's research focus is in biomedical devices, which has led to a patent. More specifically, using lasers she is interested in developing methods for breast imaging and analysis using optical spectroscopy. Dr. Kukreti graduated Bronze Tablet, Summa Cum Laude, with Bachelors of Sciences degrees in Honors Biology and Biochemistry from the University of Illinois-Urbana, Champaign in 2003. She serves a mentor for undergraduate students interested in math, science and engineering. Dr. Kukreti joined APSA as Vice President from 2007-2008. Currently she serves on the Nominations Committee of the APSA Board of Directors.
Robin G. Lorenz
Robin G. Lorenz, MD, PhD is a Professor of Pathology and Medical Education and the Associate Dean for Physician Scientist Development at the University of Alabama at Birmingham. She received her BS from Stanford University and then attended Washington University in St Louis as a Medical Scientist Training Program fellow, where in 1990 she received her MD and her PhD in immunology. She was a resident in laboratory medicine (clinical pathology) at Barnes-Jewish Hospital. In addition to directing a basic science research lab focused on chronic inflammation in the gastrointestinal tract, she is section head of the UAB Clinical Immunology Laboratory and attends on the Transfusion Medicine service. She is the past-Chair of the NIH Training, Workforce Development, and Diversity (TWD) NIGMS Study Section, is active in the AAMC GREAT Group (MD/PhD Steering Committee Chair 2011-2012), and has several publications discussing physician-scientist recruitment, training, and outcomes evaluation. She is also the Director of the UAB MSTP and she recently established the inaugural Physician Scientist Development Office at UAB. She has been recognized at the local level by the Dean’s Award for Excellence in Mentorship, the Dean’s Award for Excellence in Education Leadership, and the President’s Award for Excellence in Teaching. At the national level, she has been recognized for her outstanding achievement in clinical laboratory immunology by the ACLPS Ellis Benson Award, and for her leadership in pathology education by the ASIP Robbins Distinguished Educator Award.
David Markovitz is a Professor of Internal Medicine in the Division of Infectious Diseases at the University of Michigan who also has appointments in the programs in Cellular and Molecular Biology, Cancer Biology, and Immunology. His laboratory focuses on understanding how human cellular factors control the replication of retroviruses such as HIV. These studies are performed to both understand the biology of retroviruses and to develop possible therapies for these important human pathogens, as well as to exploit the viruses as a mechanism for understanding human cellular biology. Current interests in the laboratory focus on four areas: First, the laboratory is studying endogenous human retroviruses, retroviruses that have insinuated themselves into the human genome over the course of millions of years and now make up fully eight percent of our genomes. The Markovitz laboratory is studying whether, contrary to existing dogma, these viruses can still replicate, as well as investigating the role of these viruses and their genes in cancer and human development. These studies have also led to a strong interest in centromere genomics and biology. A second project deals with the DEK protein, which is involved in cancer causation, the pathogenesis of juvenile arthritis, and hematopoiesis. Third, the laboratory is working on a molecularly-engineered banana lectin (H84T BanLec) that holds the potential to be used in the treatment of influenza and other key pathogenic viruses such as Ebola, MERS, SARS, hepatitis C, hepatitis B, and HIV. This lectin can also be used to address mechanisms of action of the “Sugar Code”. Lastly, the Markovitz research group is studying the role of the intermediate filament protein vimentin in inflammation. These studies are carried out in conjunction with a wide variety of Ph.D. and M.D. trainees, as well as in collaboration with researchers in multiple countries. Dr. Markovitz’s work has been recognized by his election to the three principal honorary societies for academic Internal Medicine physicians: the American Society for Clinical Investigation, the Association of American Physicians, and the American Clinical and Climatological Association. Other awards include a Clinical Investigator Award from the National Cancer Institute, a Life and Health Insurance Medical Research Fund Scholar Award, a Burroughs Wellcome Clinical Scientist Award in Translational Research, and a Transformative R01 from the Office of the Director of NIH. Dr. Markovitz has had six patents issued and has five more pending approval. In addition to his research, Dr. Markovitz is a consultant on the Infectious Diseases service at the University of Michigan and Veterans Hospitals. He has also served as the Chair of the Research Committee of the Infectious Diseases Society of America and on the board of directors of the American Physician Scientist Association, as well as on the Vaccines and Related Biological Products committee of the FDA.
Kofi Mensah, MD PhD is currently in his final year of residency in the Yale physician-scientist training program (PSTP) with a clinical fellowship in rheumatology and post-doctoral research fellowship in immunobiology to follow. He is a graduate of the NIH medical-scientist training program (MSTP) at the University of Rochester where he received his PhD in immunology under the direction of Edward Schwarz, PhD and Christopher Ritchlin, MD. Part of his research was funded via the Clinical and Translational Science Institute's Predoctoral Scholar Award. His dissertation looked at immune system regulation of osteoclastogenesis in the context of inflammatory arthritis. His research won first place out of over 1,500 submissions in the basic science research category at the 2006 American College of Physicians National Medical Student Abstract Competition. His dissertation received the Melville A. Hare Award for Distinction in Research (2009). He has also had the honor of presenting his research at the American College of Rheumatology annual meeting, where he spoke as part of the REF Marshall J. Schiff, MD, Memorial Lectureship (2009), as well as at the American Society for Clinical Investigation annual meeting, the American Society for Bone and Mineral Research annual meeting and the American Academy of Orthopaedic Surgeons annual meeting. He is the co-inventor of a novel monoclonal antibody patented for use in the identification of osteoclast precursors. The antibody is currently in clinical testing as an early biomarker of inflammatory arthritis. Dr Mensah is a member of the Alpha Omega Alpha and Phi Beta Kappa honor societies. He has mentored high school, undergraduate, graduate and medical students. As part of his mentorship role, he served as a judge for the 2011 New York City Science and Engineering Fair for high school students. He has also lectured for junior medical students on the topic of immune hypersensitivity reactions. Dr Mensah has been involved with APSA since 2005, when he served as the institutional representative from the University of Rochester. In 2006, he joined the APSA public relations committee where he served as co-editor of the Phi-Psi newsletter (2007-2008). From 2008-2009, he was co-president of the public relations committee and member of the APSA executive council. Beginning in 2014, he serves on the Board of Directors with a strong interest in the physician-scientist career pipeline and establishing partnerships with specialty societies.
Evan Noch Director
Dr. Evan Noch is a fourth-year Neurology resident at Weill-Cornell Medical Center-NewYork Presbyterian Hospital in New York City in a research-track position within the lab of Lewis Cantley. He also serves as Chief Resident for Research and Education. He received his BS in Neuroscience from New York University in 2006 and his MD and PhD degrees from Temple University School of Medicine in 2013, where he studied the role of oncogenes in the regulation of oxygen and glucose metabolism in the pathogenesis of glioblastoma and medulloblastoma. During his MD and PhD training, Evan presented abstracts at several meetings, including the 10th Symposium of the International Society for Neurovirology in Milan, Italy, where he received the Volker ter Meulen Investigator-in-Training Award, and a platform presentation at the Society for Neuro-oncology’s 17th Annual Meeting. Upon completion of his PhD, Evan received the Florence Gloria Freedman Award for Cancer Research and the American Academy of Neurology 2013 Medical Student Prize for Excellence in Neurology. Evan has received travel awards to a variety of meetings, including those of the International Society for Neurovirology, the American Academy of Neurology, as well as the Central Society for Clinical and Translational Research and the Midwestern Section of the American Federation for Medical Research. Evan has been involved in APSA for 8 years, serving on the PR Committee and then as its Committee Chair before serving as President-Elect and then President. More recently, Evan has served as APSA's Resident Liaison for the past 2 years. As a resident, Evan continues to remain passionate about APSA and is now working on ways to better understand the needs of post-graduate physician-scientist trainees to improve their career development opportunities.
M. Kerry O'Banion
M. Kerry O'Banion, MD, PhD is Professor and Vice Chair in the Department of Neuroscience at the University of Rochester School of Medicine & Dentistry. He received his MD-PhD from the University of Illinois at Urbana-Champaign Medical Scholars Program in 1987 and now leads a laboratory focused on understanding the role of neuroinflammation in degenerative brain disease and following brain radiation injury. He has trained over 20 graduate students and 5 postdoctoral fellows. Dr. O'Banion directs the Medical Scientist Training Program at the University of Rochester and served as Chair of the MD-PhD Section of the Association of American Medical Colleges' Graduate Research, Education, and Training (GREAT) Group in 2009-2010. Dr. O'Banion has been a member of the APSA Board of Directors since March of 2006 and was an advisor to APSA as early as January of 2004 during APSA's initial inception. Dr. O'Banion serves on the Nominations Committee of the APSA Board of Directors and is principal investigator of an R13 grant from the National Institute of General Medical Sciences (NIGMS) that supports APSA's National Meeting.
Aylin Rodan, M.D., Ph.D. is a physician-scientist with an interest in hypertension, electrolyte disorders, and the underlying epithelial ion transport mechanisms in the kidney driving these clinical syndromes. She obtained her bachelor’s degree magna cum laude with Distinction in Biology at Yale University, where she was elected to Phi Beta Kappa, and got started in her scientific career studying the role of endoplasmic reticulum chaperones in protein folding. She then enrolled in the Medical Scientist Training Program at UCSF, where she studied the mechanisms of behavioral changes in Drosophila melanogaster in response to alcohol, examining the effects of protein kinase A signaling in different parts of the brain, as well as the role of insulin signaling. Dr. Rodan was elected to Alpha Omega Alpha as a medical student at UCSF. She continued at UCSF for internal medicine residency, then moved to Dallas for nephrology fellowship training at UT Southwestern, where she deepened her understanding of renal physiology and clinical nephrology and served as chief fellow. The next logical step was to use her favorite organism, Drosophila, to study questions of relevance to mammalian renal physiology. Using this system, her lab is now studying ion channels and transporters, and the signaling cascades that regulate them, in the Drosophila renal tubule, with funding from the National Institutes of Health and American Heart Association. This work is ongoing at the University of Utah, where Dr. Rodan is Assistant Professor of Internal Medicine/Nephrology and an investigator in the Molecular Medicine Program. The goal is to understand these transporters, channels and their regulation in greater mechanistic detail, identify new regulatory factors by performing forward genetic screens, and translate these insights into improved understanding of human kidney disorders. Additional projects study ion transport pathways in circadian rhythm and stroke. Dr. Rodan’s research has been recognized by awards from the National Kidney Foundation, American Society of Nephrology, and the Browne Genetic Research Fund. In addition to her research activities, she sees patients with kidney disorders and teaches and mentors high school, undergraduate, graduate and medical students and housestaff.
Eric Schauberger DO, PhD is a Clinical Fellow in Allergy/Immunology at Cincinnati Children's Hospital / University of Cincinnati. He completed Pediatric Residency at the Children's Hospital of Wisconsin / Medical College of Wisconsin (Milwaukee, WI) in 2015 where he received the Most Outstanding Research Award as a senior resident. He graduated from the Michigan State University College of Osteopathic Medicine's Physician Scientist Training Program in 2010 with his PhD in Genetics and DO in 2012. His dissertation title was "The identification of ATPAF1 as a novel asthma susceptibility gene and the characterization of functional regulatory variants". He received his BS with Distinction in Genetics from Iowa State University in 2003. He was awarded the Senior Leadership award by Iowa State. He has been actively involved at all levels of training and has been involved with APSA leadership including serving as Chair of the Policy committee and member of the Executive Council in 2009-10. He joined the APSA Board of Directors in July of 2011. His wife is a veterinarian and they have a menagerie of two children, one dog, two cats, one fish.
Dr. Jill Baren is Chair of the Department of Emergency Medicine and Chief of Emergency Services at the University of Pennsylvania Health System, and Professor of Emergency Medicine and Pediatrics, Perelman School of Medicine at the University of Pennsylvania.
Dr. Baren recently served as President of the Society for Academic Emergency Medicine (www.saem.org), the largest organization in the world solely dedicated to education and research in the specialty. Dr. Baren has lectured extensively, both nationally and internationally. She has published over 80 peer-reviewed articles, editorials and book chapters and is the senior editor of an evidence-based, clinically focused textbook entitled, "Pediatric Emergency Medicine.” Dr. Baren completed a Master of Bioethics degree in the Department of Medical Ethics at the University of Pennsylvania in 2004 and now serves as a faculty in the graduate degree program. She is a nationally recognized expert in the application of the federal regulations for the use of waiver of consent and the emergency exception from informed consent in clinical trials. Dr. Baren’s current research focuses on informed consent and the logistics and special protections of research subjects involved in clinical trials using emergency exception from informed consent. She is the principal investigator of the Greater Philadelphia Southern New Jersey Neurological Emergencies Treatment Trial Network, a consortium of 14 hospitals involving a research team of over 40 individuals.
David Braun, MD, PhD is the former President of APSA. He is currently a resident physician in the Department of Medicine at the Brigham and Women's Hospital and a Clinical Fellow in Medicine at Harvard Medical School. He received his MD with a Distinction in Medical Education from the Icahn School of Medicine at Mount Sinai, where he was the first Sanfurd Bluestein, MD Scholar, and from which he was received the Dr. Barry Coller Award for Excellence in Clinical Medicine. He received his PhD from the Joint Program in Computational Biology at the Courant Insitute of New York University. He graduated Magna Cum Laude from Princeton University with an A.B. in Molecular Biology, and Certificates in Engineering Biology and Computer Science. In addition to his work with APSA, Dr. Braun has served as Co-President of the Mount Sinai Chapter of Physicians for Human Rights, and as the Chief Clinic Manager of the East Harlem Health Outreach Partnership, a student-run clinic that provides free comprehensive medical care to the uninsured. In 2008, Dr. Braun was award the Excellence in Medicine Leadership Award by the American Medical Association Foundation, and the Outstanding Leadership Award by the Mount Sinai School of Medicine. Within APSA, Dr. Braun has served as President, as Chair of the Membership Committee, and as the Institutional Representative for Mount Sinai. In 2007, Dr. Braun initiated and organized the APSA New York Physician Scientists Symposium, which has since become an annual event in the Northeast that draws hundreds of trainees from dozens of institutions each year. His central goal is to help ensure that the enormous promise of translational medicine will be effectively delivered to the community and society at large.
Oscar Cuzzani, MD, PhD is a physician-scientist who specializes in ophthalmology (retina, immunology and glaucoma) with experience in phase 2-3 clinical trials and pharmacovigilance. He has seven years of experience in eye biomechanics with special emphasis in the application of finite element analysis, computational mathematics, and artificial intelligence to develop a virtual biomechanical and optical model of the eye with applications to surgery and soft testing of new compounds/delivery systems in glaucoma. His experience also extends into clinical research in AMD, uveitis (where he evaluated the link between light exposure and breakdown of the blood-ocular barrier with the aim to modulate inflammatory cascades via filtering specific spectra), and anterior segment surgery. From 2007 to 2010, he served as the Director of Clinical Research in the areas of retina and glaucoma and in pharmacovigilance at QLT Inc. Vancouver, from 2010 to 2013 as the Associate Medical Director at Abbott Labs, Abbott Park, IL. From July 2013 as Director Global Clinical Development at Allergan Inc, Irvine, CA. Since 2014 as Vice-President Clinical Science at Xoma and since February 2016 as Vice-President Clinical Development at BioTime Inc. in Alameda CA.
Ophthalmology- Retina, immunology, glaucoma. Start-up in medical devices. Clinical trials phases 2-3. Pharmacovigilance. Multidisciplinary teams: computational mathematics,engineering, biomaterials, biosensors, laser interferometry, artificial intelligence, evolutionary modeling. Scientific assessment of emerging drugs for ophthalmology. Stem cells for retinal degenerative diseases.
Dr. Jennifer Kwan is in the Physician Scientist Training Program, Internal Medicine-Cardiology track, at the University of Illinois, Chicago. She obtained her MD and PhD degrees from the Medical Scientist Training Program at the University of Illinois Chicago. She previously graduated with honors from the University of California, Berkeley with a BA in Molecular Cell Biology, where she was both a Cal Alumni Scholar and recipient of the Berkeley Academic Scholarship. She is a recipient of the University of Illinois College of Medicine leadership award, Chancellor's Service Award, Eugertha Bates Memorial Award and her PhD research on PI3K-Akt signaling, supported by an NIH T32 research fellowship, has earned her the Molecular Genetics Provost Deiss award and the Erdös Prize for Excellence in Basic Sciences. She has presented her research at various national science meetings, including the Keystone Symposia. Within APSA, Dr. Kwan previously served as the Vice President of external affairs where she helped initiate and build multiple partnerships, including with the Keystone Symposia, Association for Clinical and Translational Science (ACTS) and the American Heart Association (AHA). As the Policy Committee Chair for the past six years, she has helped design and launch several major initiatives including the F30 and Tomorrow’s Physician and developed a policy panel to address issues like biomedical research funding advocacy and policies governing intellectual property/translational research at the APSA Annual meeting. Completion of analysis of F30 survey data identified significant biomedical funding shortfalls for which APSA continues to advocate for coverage. Over the advocacy period and with support from AAMC GREAT group leaders and MD/PhD program directors, the number of NIH institutes participating in the F30 funding mechanism went from 10/27 to ALL NIH institutes. As Policy Committee chair five years ago, with input from leaders at the AAMC, ACE and AMWA, she helped develop and launch the pilot for the Tomorrow's Physician survey. The pilot is complete and data analyses from survey results have characterized future career interests of physicians and physician-scientists as well as identify significant factors that have helped or hindered their career development. Results have been accepted as peer reviewed abstracts and presented at the 2012 AAMC annual meeting and the Association for the Study of Higher Education. The Tomorrow's Physician national study results will be used to make data-based policy recommendations to help ensure the career success of physician-scientists in various career sectors, including academia, industry and government. To help with policy efforts and planning a longitudinal study to help assess factors that enable physician scientists to contribute to biomedical research, she has been in active discussions with ASCI and IOM leadership to facilitate synergistic efforts. She is also founder of the University of Illinois, College of Medicine Mentors Program that provides medical students with exposure to 26 different medical specialties and opportunities to apply and integrate their course material via real clinical cases. As a director of the APSA board of directors, Dr. Kwan plans to continue moving forward APSA initiatives and strengthen external collaborations to help reach common goals for physician-scientist career development while working to create more benefits for APSA members.
Dr. Michael Zasloff, MD, PhD, a leader in innate immunity, is a Professor of Surgery and Pediatrics at Georgetown University School of Medicine. Dr. Zasloff received his MD, PhD degrees from the New York University Medical Scientist Training Program. He completed his residency training in pediatrics at the Boston Children's Hospital and his post-doctoral training at the NIH in molecular genetics. In 1981, Dr. Zasloff was named Chief of the Human Genetics Branch of the National Institutes of Child Health and Human Development. In 1989, he became the Charles E.H. Upham Professor of Pediatrics and Genetics at the University of Pennsylvania School of Medicine and Chief of the Division of Human Genetics of the Children's Hospital of Philadelphia. He founded Magainin Pharmaceuticals, Inc. in 1988 and served as its Executive Vice President and President of the Magainin Research Institute in 1992. Dr. Zasloff became Vice Chairman of its Board of Directors during 1996-2000. He went on to serve as Dean of Research and Translational Science at the Georgetown University Medical Center, and primarily responsible for the overall management of Georgetown's biomedical research and its translation from the laboratory to patient care. Dr. Zasloff joins the APSA Board of Directors in July of 2009.